Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral ...

The molecule is semaglutide, and it's sold under the name Ozempic for type 2 diabetes and Wegovy for weight ... They are large molecule drugs, so complex in structure and must be administered by ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy ... Agrawal said Structure Therapeutics Inc.'s aleniglipron is now the ...

Pfizer has decided to discontinue development of the molecule,” Pfizer said in a statement. That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor ... markets its semaglutide drugs as Ozempic for T2D and Wegovy for weight management.